Two Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients

(April 11, 2018) – A recent study in in the journal Movement Disorders reports that clinical trials in patients with early stage Parkinson’s may benefit from assessing markers of disease progression — namely, changes in the Movement Disorder Society (MDS)-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and dopamine transporter imaging. Read more…